| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
SILVER SPRING, Md.—Just about everything seems to shift in terms of priorities, rules and limitations when it comes to the unfolding pandemic, so it should come as no surprise that U.S. FDA guidelines are a moving target as well.
 
In the latest development, the FDA has updated its guidance for performing clinical trials during the COVID-19 pandemic, and in that guidance the agency offers clarifications for managing protocol deviations and amendments. It also outlines the steps companies can take when they are considering patients getting experimental products at home instead of trial sites.
 
Finally, the updated guidance also contains three new questions and answers about the use of  video conferencing for remote participant visits, for utilization of alternate laboratory or imaging centers, and regarding post-marketing requirements for medical devices and treatments. Interestingly about the first of those three items, the FDA reports that it does not consider this kind of video conferencing to fall under the category of electronic records that are subject to 21 CFR part 11, but rather as “a live exchange of information between the personnel and trial participants.”
 
For more details, go to the FDA website at www.fda.gov and look for the “FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Public Health Emergency” document that was first issued in March 2020.

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gold circles with attached purple corkscrew shapes represent gold nanoparticles against a black background.

Driving gene therapy with nonviral vectors 

Learn why nonviral vectors are on the rise in gene therapy development.
A 3D digital illustration of a viral spike protein on a cell surface, surrounded by colorful, floating antibodies in the background

Milestone: Leapfrogging to quantitative, high throughput protein detection and analysis

Researchers continuously push the boundaries of what’s possible with protein analysis tools.
Blue cancer cells attached to a cellular surface against a bright blue background in a 3D rendering of a cancer infection.

Advancing immuno-oncology research with cellular assays

Explore critical insights into immunogenicity and immunotoxicity assays for cancer therapies.
Drug Discovery News November 2024 Issue
Latest IssueVolume 20 • Issue 6 • November 2024

November 2024

November 2024 Issue

Explore this issue